Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)-Reference-Cited by-同舟云学术

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)

Published:2017-01-31 Issue:5 Volume:31 Page:1240-1243
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Chanan-Khan A,Egyed M,Robak T,Martinelli de Oliveira F A,Echeveste M A,Dolan S,Desjardins P,Blonski J Z,Mei J,Golany N,Zhang J,Gribben J G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201747.pdf

Reference7 articles.

1. Chen CI, Bergsagel PL, Paul H, Xu W, Lau A, Dave N et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 1175–1181.

2. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011; 118: 3489–3498.

3. Chanan-Khan A, Miller KC, Musail L, Lawrence D, Padmanabhan S, Takeshita K et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343–5349.

4. Ferrajoli A, Lee BN, Schlette E, O’Brien SM, Gao H, Wen S et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291–5297.

5. Rai K, Peterson BL, Applebaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton’s tyrosine kinase inhibitors (BTKis) single and its combination therapy;Expert Opinion on Drug Safety;2024-03-18

2. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis;The Lancet Haematology;2022-12

3. Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?;Hematology/Oncology Clinics of North America;2021-08

4. Affinity-Based Polymers Provide Long-Term Immunotherapeutic Drug Delivery Across Particle Size Ranges Optimal for Macrophage Targeting;Journal of Pharmaceutical Sciences;2021-04

5. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia;Frontiers in Immunology;2020-11-18